Merck (MRK) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Merck's Q4 2024 results surpassed expectations, driven by strong oncology sales and growth in Keytruda. See why I think MRK may work for income investors.

Prevymis recorded sales of $215 million, up 23% year over year. Januvia/Janumet (diabetes) franchise sales declined 36% year over year to $487 million. The drug’s sales were hurt by lower ...